simenepag isopropyl

Simenepag isopropyl (AGN-210669) is a small molecule prodrug of the active metabolite simenepag (AGN-210676). It functions as a potent and selective agonist of the prostaglandin E2 receptor 2 (EP2), with an EC50 of approximately 5 nM. Developed by Allergan (now part of AbbVie), the drug was investigated for the treatment of open-angle glaucoma and ocular hypertension. Its mechanism of action involves the selective activation of the EP2 receptor to facilitate aqueous humor outflow, thereby reducing intraocular pressure (IOP). This pathway is distinct from the FP receptor-mediated mechanism utilized by common prostaglandin analogs like latanoprost. Although it reached clinical trials, development of this specific candidate appears to have stalled or been discontinued in favor of other assets.

Other names

simenepag isopropyl ester